India has been one of the major global players in the development of generic drugs, continues to gain visibility in the development of new drugs, and is one of the major geographies for conducting multinational clinical trials. Learn how intergovernmental initiatives and partnerships between India's Drug Regulatory Department (DCGI office) and USFDA, Health Canada, MHRA and EMEA would add to India's role in the development of new medicines.
Explore
